<DOC>
	<DOCNO>NCT01849848</DOCNO>
	<brief_summary>The purpose study determine antitumor efficacy safety bendamustine ( SyB L-0501 : 90 mg/m^2/day ) maximum 6 cycle ( 1 cycle : intravenous administration 2 consecutive day 26-day observation period ) patient relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Study SyB L-0501 Treat Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Patients diagnose multiple myeloma basis response criterion International Myeloma Working Group ( IMWG ) confirm meet one follow criterion : ( definition progression accord IMWG response criterion ) 25 % increase compare baseline follow value Serum Mprotein level ( however , absolute value 0.5 g/dL high ) Urine Mprotein level ( however , absolute value 200 mg/24 hour higher ) For lesion without measurable serum urine Mprotein value . involved/uninvolved free light chain ( FLC ) ratio ( however , absolute value 10 mg/dL high ) Clear appearance new bone lesion soft tissue plasmacytoma apparent growth size current bone lesion soft tissue plasmacytoma Appearance hypercalcemia ( corrected calcium level ≥ 11.5 mg/dL determine cause solely myelomas ) 2 . Patients measurable lesion ( meet least one follow two criterion Serum Mprotein [ Immunoglobulin G ( IgG ) ≥ 1.0 g/dL , Immunoglobulin A ( IgA ) ≥ 0.5 g/dL , Immunoglobulin D ( IgD ) ≥ 0.1 g/dL ) Urine Mprotein ≥ 200 mg/24 hour 3 . Patients meet either one follow item prior chemotherapy use proteasome inhibitor , Immunomodulatory Drugs ( IMiDs ) ( thalidomide lenalidomide ) alkylating agent . No response* Relapse/recurrence response* Intolerance Not applicable ( reason confirm source document ) predict aggravation complication ( neurotoxicity , etc . ) * Patients whose disease progress base IMWG response criterion receive recent therapy 4 . Patients undergone washout period 3 week end previous therapy determine effect previous treatment ( antitumor effectiveness ) . 5 . Patients expect survive least 3 month 6 . Patients age 20 79 year time interim registration 7 . Performance Status ( P.S . ) 0 125 . However , P.S . 2 due pain lytic bone lesion acceptable 8 . Patients adequately maintain organ function ( e.g. , bone marrow , heart , lung , liver , kidney function ) Neutrophil count : ≥ 1,500 /mm^3 Platelet count : ≥ 75,000 /mm^3 Albumin : ≥ 2.5 g /dL Aspartate aminotransferase ( AST ) Glutamic oxaloacetic transaminase ( GOT ) : &lt; 3.0 time upper limit normal range site Alanine aminotransferase ( ALT ) Glutamic pyruvic transaminase ( GPT ) : &lt; 3.0 time upper limit normal range site Total bilirubin : &lt; 1.5 time upper limit normal range site Serum creatinine : &lt; 3.0 time upper limit normal range site Partial pressure O2 ( PaO2 ) ≥ 65 mmHg No abnormality require treatment detect ECG Left ventricular ejection fraction ( LVEF ) ( echocardiography ) : ≥ 55 % 9 . Patients provide write consent participation study 1 . Patients apparent infection ( include viral infection ) 2 . Patients serious complication ( hepatic renal dysfunction , etc . ) 3 . Patients complication medical history serious cardiac disease ( e.g. , myocardial infarction , ischemic heart disease ) within 2 year date interim registration patient arrhythmias require treatment 4 . Patients serious gastrointestinal symptom ( e.g. , severe nausea , vomit , diarrhea ) 5 . Patients positive Hepatitis B surface ( HBs ) antigen , Hepatitis C virus ( HCV ) antibody , HIV antibody 6 . Patients serious bleed tendency ( e.g. , disseminate intravascular coagulation : DIC ) 7 . Patients , confirm past , interstitial pneumonia , pulmonary fibrosis , pulmonary emphysema require treatment . 8 . Patients complication apparent cardiac amyloidosis 9 . Patients infiltration central nervous system ( CNS ) patient clinical symptom suspect infiltration CNS , 10 . Patients active multiple primary cancer 11 . Patients , confirm past , autoimmune hemolytic anemia 12 . Patients receive investigational product past 13 . Patients receive allogeneic stem cell transplant past . ( patient receive autologous stem cell transplantation acceptable ) 14 . Patients receive cytokine preparation erythropoietin granulocyte colony stimulate factor ( GCSF ) blood transfusion within 1 week prior examination conduct interim registration study 15 . Patients receive investigational product unapproved medication within 3 month interim registration study 16 . Patients prior allergy medication similar investigational product ( e.g. , alkylating agent , purinenucleoside derivative ) mannitol 17 . Patients drug addiction , narcotic addiction , and/or alcohol dependency 18 . Patients pregnant , may possibly pregnant , lactate 19 . Patients agree practice contraception follow period : Male : During investigational product administration 6 month final administration Female : During investigational product administration 4 month final administration 20 . Patients otherwise judge investigator subinvestigator unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>